



## Guidelines March

## COVID-19

**To date, current data do not allow highlighting a treatment to standard therapeutic management.  
Clinical trials are underway**

**This document incorporates the latest French national recommendations.  
Assessing the risks/benefits of each prescription remains fundamental.**

- Confirmed non-serious or ambulatory COVID+ patients : **standard therapeutic management**
- Confirmed COVID+ patients hospitalized with signs of severity (requiring supplementary oxygen therapy) :  
except patient in critical condition not subject to resuscitation
  - ✓ **STANDARD THERAPEUTIC MANAGEMENT**
  - ✓ **HYDROXYCHLOROQUINE 200mg, 2 tablets twice daily at D1 then one tablet twice daily from D2 to D5** in the absence of contra-indications (risk of ventricular rhythm disorder) and after completing an ECG to evaluate the QT interval. (Yao X. et al. *Clinical Infectious Diseases*; doi.org/10.1093/cid/ciaa237)
  - ✓ **HYDROXYCHLOROQUINE + AZITHROMYCIN**
    - **Please note: the association increases the risk of cardiac toxicity.**
    - The absence of data on this association justifies that its use can enter into a therapeutic evaluation process
  - ✓ **LOPINAVIR/RITONAVIR 200mg/50mg 2 tablets twice daily during 5 days**, in the absence of contra-indications.
    - **Only in patients with symptoms for last than 10 days** (Cao B. et al. *NEJM*, DOI: 10.1056/NEJMoa2001282)
    - **Avoid lopinavir/ritonavir and hydroxychloroquine association due to an increased risk of cardiac toxicity.**
      - **Contact the clinical pharmacist of your care units to set up these treatments.**
- Confirmed COVID+ patients hospitalized in intensive care units with respiratory distress syndrom :
  - ✓ **IDEM ABOVE**
  - ✓ **REMDESIVIR IV 200mg loading dose then 100mg / d for 10 days**  
The request for access to treatment must be made directly by the department doctor to the pharmaceutical laboratory via the following link :<https://rdvcu.gilead.com/>  
You will also find on this link, the restrictions on this drug availability.

**For the delivery to the pharmacy part, it is imperative to faithfully enter the informations below during the request so that the treatments can be delivered.**

If Approved - Where are we shipping the investigational drug?

To whom are we delivering the product (The contact below must be reachable with 24 hour availability)

Pharmacy/Hospital Name\*

HOPITAUX UNIVERSITAIRES POLE LOGISTIQUE PHARMACIE

Pharmacist/Pharmacy Contact Name\*

DR BENEDICTE GOURIEUX

Address\*

70 RUE DE L'ENGELBREIT - 67200 STRASBOURG

E-Mail\*

pharmacie-contact@chru-strasbourg.fr

Phone\*

0369553368

Cell Phone\*

0621570403

- ✓ **Immunomodulatory treatments, not first-line**, under evaluation in therapeutic trials.

**Question or additional informations:** [seniorsSMIT@chru-strasbourg.fr](mailto:seniorsSMIT@chru-strasbourg.fr) or [pharmacie-contact@chru-strasbourg.fr](mailto:pharmacie-contact@chru-strasbourg.fr)

Creation :		Modification :		Validation :	
10/03/2020	CAI	24/03/2020	CAI	26/03/2020	COMEDIMS
Page 1/2					



## Guidelines April

## COVID-19

**To date, current data do not allow highlighting a treatment to standard therapeutic management.  
Clinical trials are underway**

**This document incorporates the latest French national recommendations.  
Assessing the risks/benefits of each prescription remains fundamental.**

- Confirmed non-serious or ambulatory COVID+ patients : **standard therapeutic management**
- Confirmed COVID+ patients hospitalized with signs of severity (requiring supplementary oxygen therapy) : except patient in critical condition not subject to resuscitation
- ✓ **STANDARD THERAPEUTIC MANAGEMENT**
- ✓ **HYDROXYCHLOROQUINE 200mg** in the absence of contra-indications (risk of ventricular rhythm disorder) and after completing an ECG to evaluate the QT interval
- ✓ Protocol for therapeutic use (PTU) – French national recommendations – date : 3/30/20
- ✓ **HYDROXYCHLOROQUINE + AZITHROMYCIN**
  - **Have not been proven effective and increase the risk of QT interval prolongation.**
  - **Must only be prescribed as part of a clinical trial.**
- ✓ **LOPINAVIR/RITONAVIR 200mg/50mg**, in the absence of contra-indications.
  - **Protocol for therapeutic use (PTU) – French national recommendations** – date : 3/30/20
  - **Only in patients with symptoms lasting more than 10 days.** (Cao B. et al. NEJM, DOI: 10.1056/NEJMoa2001282)
  - **Avoid lopinavir/ritonavir and hydroxychloroquine association due to an increased risk of cardiac toxicity.**
    - **Contact the clinical pharmacist of your care units to set up these treatments.**
- Confirmed COVID+ patients hospitalized in intensive care units with respiratory distress syndrom :
- **IDEM ABOVE**
- **REMDESIVIR IV** : limited indications
- European Discoverytrial Discovery
- Pregnant women or children under 18 years with confirmed COVID-19 and severe manifestations of the disease: <https://rdvcu.gilead.com/>

**Question or additional information** : [seniorsSMIT@chru-strasbourg.fr](mailto:seniorsSMIT@chru-strasbourg.fr) ou [pharmacie-contact@chru-strasbourg.fr](mailto:pharmacie-contact@chru-strasbourg.fr)

Creation :		Modification :		Validation :	
10/03/2020	CAI	3/04/2020	CAI	3/04/2020	COMEDIMS
Page 2/2					